Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

GoPro, Krispy Kreme, and Kohl’s surge as meme stock mania returns. Retail traders drive volatility in a high-liquidity, ...

Intel is scheduled to report second-quarter results after the closing bell Thursday, with analysts tracked by Visible Alpha unanimously neutral amid questions surrounding the company's foundry ...

Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...

PennyMac Financial Services' Q2 2025 earnings reveal $136M net income, AI-driven cost-saving plans, and market share growth ambitions.

Amgen saw its price target boosted from $315 to $326 by UBS Group, maintaining a neutral stance. This upgrade reflects a ...